Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Rhea-AI Summary

Eliem Therapeutics, a clinical-stage biotechnology firm, will participate in two investor conferences in November 2022. The first is Guggenheim’s 4th Annual Immunology and Neurology Conference on November 15, where a fireside chat is scheduled for 10:10 a.m. ET. The second is the Stifel 2022 Healthcare Conference on November 16, with a fireside chat at 1:50 p.m. ET. Both events will be webcasted live on their website and archived for 30 days. Eliem focuses on developing therapies for neuronal excitability disorders, addressing unmet needs in various medical fields.

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Guggenheim’s 4th Annual Immunology and Neurology Conference
Fireside Chat Date: November 15, 2022
Fireside Chat Time: 10:10 a.m. ET
Location: St. Regis Hotel, New York, NY

Stifel 2022 Healthcare Conference
Fireside Chat date: Wednesday, November 16, 2022
Fireside Chat time: 1:50 p.m. ET
Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the fireside chat presentations will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay of each of the events will remain available on Eliem’s website for at least 30 days after the event.

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

https://eliemtx.com/

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media
Marites Coulter
Verge Scientific
Mcoulter@vergescientific.com
415.819.2214

FAQ

What are the details of Eliem Therapeutics' participation in investor conferences?

Eliem Therapeutics will participate in Guggenheim’s 4th Annual Immunology and Neurology Conference on November 15, 2022, at 10:10 a.m. ET, and the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET.

Where can I watch the live presentations from Eliem Therapeutics?

Live presentations from Eliem Therapeutics will be available on their Investors section of the website during the events.

What is the focus of Eliem Therapeutics?

Eliem Therapeutics focuses on developing therapies for neuronal excitability disorders, addressing unmet needs in psychiatry, epilepsy, chronic pain, and other neurological conditions.

How long will the archived replays of the events be available?

Archived replays of the events will remain available on Eliem Therapeutics' website for at least 30 days after the events.

What is the significance of Eliem Therapeutics' investor conferences?

The investor conferences provide an opportunity for Eliem Therapeutics to discuss their advancements and potential therapies for neuronal excitability disorders with investors and stakeholders.